RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

Ph Gabriel Steg, Shamir R Mehta, J Wouter Jukema, Gregory Y.H. Lip, C Michael Gibson, Frantisek Kovar, Petr Kala, Alberto Garcia-Hernandez, Ronny W Renfurm, Christopher B Granger, RUBY-1 Investigators, Christian Tobias Torp-Pedersen

    151 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome'. Together they form a unique fingerprint.

    Medicine & Life Sciences